Skip to Content

Regenicin Inc - Stock Quote RGIN

Rating as of

Morningstar's Regenicin Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - RGIN

Regenicin Inc's Company Profile

Business Description

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base.

10 High Court
Little Falls, NJ, 07424
T +1 973 557-8914
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Sep 30, 2022
Stock Type Cyclical
Employees 3